Top Stories
Deep Origin identified multiple small-molecule hits against a novel target in under three months, which BioAge validated in its lab.
Generate is eligible for close to $1.2 billion in milestones under the deal, which will leverage its Generate Platform to design multispecific therapeutics for metabolic diseases.
Through the takeout, Agilent will add FDA-cleared diagnostic software and pathology data to further its biomarker research offerings.
The Eleven Therapeutics spinout is starting with kidney and vascular diseases, where it says known genetic targets have remained difficult to reach with existing medicines.
The goal of the collaboration is to standardise tissue analysis and accelerate biomarker research, supporting drug development efforts.
Conference News
New blood-based pathogen test enables unbiased detection of more than 68,000 bacteria, fungi, DNA and RNA viruses, and parasites with next-day results.IDWeek presentations highlight Delve Detect’s imp...
DURHAM, N.C., Oct. 14, 2026 (GLOBE NEWSWIRE) -- GeneCentric, a company making precision medicine more precise by bringing gene expression biology to liquid biopsy, today announced that it will present...
The program reads multiple layers of biology from one sample, including circular RNA, and studies patterns across large patient populations. Decode Health will share new research at the ACTRIMS-ECTRIM...
Study demonstrated 93.3% sensitivity, 92.4% specificity and 99.9% negative predictive value for eyonis® LCSeyonis® LCS is the first and only FDA-cleared AI/ML-based Software as a Medical Device combin...
DETECT-ME study across 18 U.S. sites shows near 100% sensitivity for dysplasia and cancer, supporting a scalable, non-endoscopic front door into the diagnostic pathwayNASHVILLE, Tenn.--(BUSINESS WIRE)...
